XBIT (XBiotech Inc)
Insider Trading Activity
Every open-market purchase and sale reported by XBIT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-12 | Tevi David Troy | Director | A | — | — |
| 2025-11-12 | Thomas Martin Kuendig | Director | A | — | — |
| 2025-11-12 | David Spencer Soffer | Director | A | — | — |
| 2025-11-12 | Craig Evan Rademaker | Director | A | — | — |
| 2025-03-19 | JOHN SIMARD | Chief Executive Officer | A | — | — |
| 2025-02-04 | JOHN SIMARD | Chief Executive Officer | J | — | — |
| 2024-06-21 | Donald H. MacAdam | Director | A | — | — |
| 2024-06-21 | Peter Libby | Director | A | — | — |
| 2024-06-21 | Jan-Paul Waldin | Director | A | — | — |
| 2024-06-21 | W THORPE MCKENZIE | Director | A | — | — |
| 2024-01-05 | JOHN SIMARD | Chief Executive Officer | Buy | — | — |
| 2023-06-26 | Jan-Paul Waldin | Director | A | — | — |
| 2023-06-26 | Donald H. MacAdam | Director | A | — | — |
| 2023-06-26 | W THORPE MCKENZIE | Director | A | — | — |
| 2023-06-26 | Peter Libby | Director | A | — | — |
| 2023-02-17 | SUSHMA SHIVASWAMY | Chief Scientific Officer | A | — | — |
| 2022-06-27 | Donald H. MacAdam | Director | A | — | — |
| 2022-06-27 | W THORPE MCKENZIE | Director | A | — | — |
| 2022-06-27 | Jan-Paul Waldin | Director | A | — | — |
| 2022-06-27 | Peter Libby | Director | A | — | — |
| 2022-02-15 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2022-01-13 | W THORPE MCKENZIE | Director | MIXED | — | — |
| 2021-11-23 | SUSHMA SHIVASWAMY | Chief Scientific Officer | A | — | — |
| 2021-11-23 | QUEENA HAN | VP Finance & HR | A | — | — |
| 2021-10-15 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-10-06 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-10-01 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-09-28 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-09-22 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-07-19 | JOHN SIMARD | Chief Executive Officer | Sell | — | — |
| 2021-07-12 | Donald H. MacAdam | Director | M | — | — |
| 2021-07-12 | Peter Libby | Director | M | — | — |
| 2021-06-24 | Peter Libby | Director | A | — | — |
| 2021-06-24 | Donald H. MacAdam | Director | A | — | — |
| 2021-06-24 | Jan-Paul Waldin | Director | A | — | — |
| 2021-06-24 | W THORPE MCKENZIE | Director | A | — | — |
| 2021-04-27 | Peter Libby | Director | A | — | — |
| 2021-04-27 | JOHN SIMARD | Chief Executive Officer | A | — | — |
| 2021-03-22 | JOHN SIMARD | Chief Executive Officer | M | — | — |
| 2021-02-01 | JOHN SIMARD | Chief Executive Officer | W | — | — |
| 2020-12-18 | BAY STREET FINANCIAL S.A. | 10%+ Owner | Sell | — | — |
| 2020-12-02 | BAY STREET FINANCIAL S.A. | 10%+ Owner | Sell | — | — |
| 2020-11-20 | W THORPE MCKENZIE | Director | Sell | — | — |
| 2020-09-21 | JOHN SIMARD | Chief Executive Officer | J | — | — |
| 2020-09-16 | SUSHMA SHIVASWAMY | Chief Scientific Officer | MIXED | — | — |
| 2020-09-02 | QUEENA HAN | VP Finance & HR | M | — | — |
| 2020-09-01 | Donald H. MacAdam | Director | A | — | — |
| 2020-09-01 | W THORPE MCKENZIE | Director | A | — | — |
| 2020-09-01 | Jan-Paul Waldin | Director | A | — | — |
| 2020-09-01 | JOHN SIMARD | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,914,111 | — |
| — | Chief Executive Officer | 3,823,166 | — |
| — | Director | 2,877,712 | — |
| — | 10%+ Owner | 1,981,515 | — |
| — | Director | 200,243 | — |
| — | 10%+ Owner | 110,282 | — |
| — | VP Finance & HR | 30,000 | — |
| — | Director | 25,000 | — |
| — | Director | 10,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XBIT quote page; the site-wide leaderboard is on the insider transactions hub.